Literature DB >> 9694159

Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency.

S Tsujino1, N Kinoshita, T Tashiro, K Ikeda, N Ichihara, H Kikuchi, Y Hagiwara, M Mizutani, T Kikuchi, N Sakuragawa.   

Abstract

Acid maltase deficiency (AMD) causes a lysosomal glycogenosis inherited as an autosomal recessive trait. The infantile type of AMD (Pompe disease) leads to early death due to severe dysfunction of cardiac and respiratory muscles and no effective therapy is available. Replication-defective adenovirus vectors offer a promising tool for in vivo gene delivery and gene therapy. We constructed a recombinant adenovirus containing the human acid maltase (AM) cDNA downstream of the CAG promoter, composed of modified chicken beta-actin promoter and CMV IE enhancer (AxCANAM). Japanese quail with AMD was used for this study as an animal model for human AMD. When cultured fibroblasts from AMD quail were infected with AxCANAM, AM activity in the cells increased in proportion to the multiplicity of infection (MOI). When AxCANAM (4.5 x 10(8) PFU) was injected into unilateral superficial pectoral muscle of AMD quail, PAS staining showed that glycogenosomes disappeared and stainability of acid phosphatase was reduced in the injected area as compared with the contralateral muscle of the same birds. Biochemically, AM activity increased and glycogen content decreased in the injected muscle. Western blot analysis showed that AMD quail muscle injected with AxCANAM expressed human AM protein processed to active forms. These results suggest that the human AM cDNA transferred by an adenovirus vector was sufficiently expressed, leading to a marked reduction of the glycogen accumulation in the skeletal muscle of AMD quail.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694159     DOI: 10.1089/hum.1998.9.11-1609

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  6 in total

1.  A modified PAS stain combined with immunofluorescence for quantitative analyses of glycogen in muscle sections.

Authors:  Gert Schaart; Reinout P Hesselink; Hans A Keizer; Gerrit van Kranenburg; Maarten R Drost; Matthijs K C Hesselink
Journal:  Histochem Cell Biol       Date:  2004-08-03       Impact factor: 4.304

Review 2.  Progress and problems when considering gene therapy for GSD-II.

Authors:  A Kiang; A Amalfitano
Journal:  Acta Myol       Date:  2007-07

3.  Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase.

Authors:  A Amalfitano; A J McVie-Wylie; H Hu; T L Dawson; N Raben; P Plotz; Y T Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 4.  Progress and challenges of gene therapy for Pompe disease.

Authors:  Giuseppe Ronzitti; Fanny Collaud; Pascal Laforet; Federico Mingozzi
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  Adeno-associated virus-mediated gene therapy for metabolic myopathy.

Authors:  Cathryn S Mah; Meghan S Soustek; A Gary Todd; Angela McCall; Barbara K Smith; Manuela Corti; Darin J Falk; Barry J Byrne
Journal:  Hum Gene Ther       Date:  2013-11       Impact factor: 5.695

Review 6.  News and views in Histochemistry and Cell Biology.

Authors:  Esther Asan; Detlev Drenckhahn
Journal:  Histochem Cell Biol       Date:  2004-12-22       Impact factor: 2.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.